Sfoglia per Autore
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia
2025 Saettini, F; Guerra, F; Mauri, M; Salter, C; Adam, M; Adams, D; Baple, E; Barredo, E; Bhatia, S; Borkhardt, A; Brusco, A; Bugarin, C; Chinello, C; Crosby, A; D'Souza, P; Denti, V; Fazio, G; Giuliani, S; Kuehn, H; Amel, H; Elmi, A; Lo, B; Malighetti, F; Mandrile, G; Martín-Nalda, A; Mefford, H; Moratto, D; Emam Mousavi, F; Nelson, Z; Gutiérrez-Solana, L; Macnamara, E; Michaud, V; O'Leary, M; Pagani, L; Pavinato, L; Santamaria, P; Planas-Serra, L; Quadri, M; Raspall-Chaure, M; Rebellato, S; Rosenzweig, S; Roubertie, A; Holzinger, D; Deal, C; Vockley, C; Savino, A; L. Stoddard, J; Uhlig, H; Pujol, A; Magni, F; Paglia, G; Cazzaniga, G; Piazza, R; Barberis, M; Biondi, A
Idiopathic erythrocytosis: a germline disease?
2024 Elli, E; Mauri, M; D’Aliberti, D; Crespiatico, I; Fontana, D; Redaelli, S; Pelucchi, S; Spinelli, S; Manghisi, B; Cavalca, F; Aroldi, A; Ripamonti, A; Ferrari, S; Palamini, S; Mottadelli, F; Massimino, L; Ramazzotti, D; Cazzaniga, G; Piperno, A; Gambacorti-Passerini, C; Piazza, R
Cytogenetically Balanced Reciprocal Translocation Could Hide Molecular Genomic Unbalances: Implications for Foetal Phenotype Correlation
2024 Villa, N; Redaelli, S; Farina, S; Sala, E; Crosti, F; Cozzolino, S; Verderio, M; Dalpra, L; Roversi, G; Bentivegna, A; Cazzaniga, G; Lavitrano, M; Conconi, D
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation
2024 Bettini, L; Fazio, G; Saitta, C; Piazza, R; Palamini, S; Buracchi, C; Rebellato, S; Santoro, N; Simone, C; Biondi, A; Cazzaniga, G
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
2024 Crespiatico, I; Zaghi, M; Mastini, C; D'Aliberti, D; Mauri, M; Mercado, C; Fontana, D; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Sangiorgio, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti Passerini, C; Elli, E; Mologni, L; Piazza, R
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
2024 Conter, V; Valsecchi, M; Cario, G; Zimmermann, M; Attarbaschi, A; Stary, J; Niggli, F; Dalla Pozza, L; Elitzur, S; Silvestri, D; Locatelli, F; Moricke, A; Engstler, G; Smisek, P; Bodmer, N; Barbaric, D; Izraeli, S; Rizzari, C; Boos, J; Buldini, B; Zucchetti, M; Von Stackelberg, A; Matteo, C; Lehrnbecher, T; Lanvers-Kaminsky, C; Cazzaniga, G; Gruhn, B; Biondi, A; Schrappe, M
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
2023 Palmi, C; Bresolin, S; Junk, S; Fazio, G; Silvestri, D; Zaliova, M; Oikonomou, A; Scharov, K; Stanulla, M; Moericke, A; Zimmermann, M; Schrappe, M; Buldini, B; Bhatia, S; Borkhardt, A; Saitta, C; Galbiati, M; Bardini, M; Lo Nigro, L; Conter, V; Valsecchi, M; Biondi, A; Te Kronnie, G; Cario, G; Cazzaniga, G
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
2023 Oikonomou, A; Valsecchi, L; Quadri, M; Watrin, T; Scharov, K; Procopio, S; Tu, J; Vogt, M; Savino, A; Silvestri, D; Valsecchi, M; Biondi, A; Borkhardt, A; Bhatia, S; Cazzaniga, G; Fazio, G; Bardini, M; Palmi, C
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica]
2023 Bettini, L; Lauriola, R; Vendemini, F; Coliva, T; Biondi, A; Cazzaniga, G
The recombinome of IKZF1 deletions in B-cell precursor ALL
2023 Lopes, B; Meyer, C; Bouzada, H; Kulp, M; Maciel, A; Larghero, P; Barbosa, T; Poubel, C; Barbieri, C; Venn, N; Pozza, L; Barbaric, D; Palmi, C; Fazio, G; Saitta, C; Aguiar, T; Lins, M; Ikoma-Colturato, M; Schramm, M; Chapchap, E; Cazzaniga, G; Sutton, R; Marschalek, R; Emerenciano, M
Antibody Deficiency in Patients with Biallelic KARS1 Mutations
2023 Saettini, F; Guerra, F; Fazio, G; Bugarin, C; Mcmillan, H; Ohtake, A; Ardissone, A; Itoh, M; Giglio, S; Cappuccio, G; Giardino, G; Romano, R; Quadri, M; Gasperini, S; Moratto, D; Chiarini, M; Akira, I; Fukuhara, Y; Hayakawa, I; Okazaki, Y; Mauri, M; Piazza, R; Cazzaniga, G; Biondi, A
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation
2023 Barone, C; Orsenigo, R; Cazzola, A; D'Errico, E; Patelli, A; Quattrini, G; Vergani, B; Bombelli, S; De Marco, S; D'Orlando, C; Bianchi, C; Leone, B; Meneveri, R; Biondi, A; Cazzaniga, G; Rabbitts, T; Brunelli, S; Azzoni, E
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease
2023 Caserta, C; Nucera, S; Barcella, M; Fazio, G; Naldini, M; Pagani, R; Pavesi, F; Desantis, G; Zonari, E; D'Angio, M; Capasso, P; Lombardo, A; Merelli, I; Spinelli, O; Rambaldi, A; Ciceri, F; Silvestri, D; Valsecchi, M; Biondi, A; Cazzaniga, G; Gentner, B
Correction to: Antibody Deficiency in Patients with Biallelic KARS1 Mutations (Journal of Clinical Immunology, (2023), 43, 8, (2115-2125), 10.1007/s10875-023-01584-7)
2023 Saettini, F; Guerra, F; Fazio, G; Bugarin, C; Mcmillan, H; Ohtake, A; Ardissone, A; Itoh, M; Giglio, S; Cappuccio, G; Giardino, G; Romano, R; Quadri, M; Gasperini, S; Moratto, D; Chiarini, M; Ishiguro, A; Fukuhara, Y; Hayakawa, I; Okazaki, Y; Mauri, M; Piazza, R; Cazzaniga, G; Biondi, A
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
2023 Hunger, S; Tran, T; Saha, V; Devidas, M; Valsecchi, M; Gastier-Foster, J; Cazzaniga, G; Reshmi, S; Borowitz, M; Moorman, A; Heerema, N; Carroll, A; Martin-Regueira, P; Loh, M; Raetz, E; Schultz, K; Slayton, W; Cario, G; Schrappe, M; Silverman, L; Biondi, A
Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
2023 Bomken, S; Enshaei, A; Schwalbe, E; Mikulasova, A; Dai, Y; Zaka, M; Fung, K; Bashton, M; Lim, H; Jones, L; Karataraki, N; Winterman, E; Ashby, C; Attarbaschi, A; Bertrand, Y; Bradtke, J; Buldini, B; Burke, G; Cazzaniga, G; Gohring, G; De Groot-Kruseman, H; Haferlach, C; Nigro, L; Parihar, M; Plesa, A; Seaford, E; Sonneveld, E; Strehl, S; Van der Velden, V; Rand, V; Hunger, S; Harrison, C; Bacon, C; Van Delft, F; Loh, M; Moppett, J; Vormoor, J; Walker, B; Moorman, A; Russell, L
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
2022 Stutterheim, J; de Lorenzo, P; van der Sluin, I; Alten, J; Ancliffe, P; Attarbaschi, A; Aversa, L; Boer, J; Biondi, A; Brethon, B; Diaz, P; Cazzaniga, G; Escherich, G; Ferster, A; Kotecha, R; Lausen, B; Leung, A; Locatelli, F; Silverman, L; Stary, J; Szczepanski, T; van der Velden, V; Vora, A; Zuna, J; Schrappe, M; Valsecchi, M; Pieters, R
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
2022 Buchmann, S; Schrappe, M; Baruchel, A; Biondi, A; Borowitz, M; Campbell, M; Cario, G; Cazzaniga, G; Escherich, G; Harrison, C; Heyman, M; Hunger, S; Kiss, C; Liu, H; Locatelli, F; Loh, M; Manabe, A; Mann, G; Pieters, R; Pui, C; Rives, S; Schmiegelow, K; Silverman, L; Stary, J; Vora, A; Brown, P
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia
2022 Kulp, M; Siemund, A; Larghero, P; Dietz, A; Alten, J; Cario, G; Eckert, C; Caye-Eude, A; Cave, H; Bardini, M; Cazzaniga, G; De Lorenzo, P; Valsecchi, M; Diehl, L; Bonig, H; Meyer, C; Marschalek, R
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
2022 Locatelli, F; Lo Nigro, L; Andriano, N; Buldini, B; Silvestri, D; Villa, T; Parasole, R; Barisone, E; Testi, A; Biondi, A; Valsecchi, M; Rizzari, C; Conter, V; Basso, G; Cazzaniga, G
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile